Jasper Therapeutics (JSPR) vs Scilex (SCLX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Scilex (SCLX) has outperformed Jasper Therapeutics (JSPR) over the past year, losing 73.0% versus a loss of 76.7%. Over five years, SCLX leads with a -98.6% price change compared with -99.7% for JSPR. Scilex is the larger company by market cap ($20.8 million vs $18.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | JSPR | SCLX |
|---|---|---|
| Share price | $0.56 | $2.96 |
| Market cap | $18.63M | $20.82M |
| 1-day change | -1.70% | -15.19% |
| YTD return | -69.40% | -61.03% |
| 1-year return | -76.67% | -72.96% |
| 5-year return | -99.66% | -98.65% |
| Forward P/E | — | 4.05 |
| EPS (TTM) | $-1.04 | $-49.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.69 | $16.81 |
| 52-week low | $0.315 | $2.62 |
| Distance from 52-week high | -79.18% | -82.39% |
| Analyst consensus | none | — |
| Avg. price target upside | +3471.43% | — |
| Average volume | 1.37M | 53.62K |
| Shares outstanding | 33.27M | 7.03M |
| Employees | — | 34 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Drug Manufacturers - General |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Jasper Therapeutics
JSPR stock →Jasper Therapeutics, Inc., a clinical stage biotechnology company, focuses on the design and development of therapies to treat immune-mediated diseases. It is advancing a pipeline of medicines, including KP-104, a dual-complement inhibitor that has demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH) and is under evaluation in other unmet need nephrology disorders; Briquilimab is an anti-KIT antibody, which has demonstrated clinical results as a conditioning agent for stem cell transplant and mast cell mediated diseases, such as chronic urticarias and allergic asthma; and KP-701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders.
Healthcare · Biotechnology
About Scilex
SCLX stock →Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
Healthcare · Drug Manufacturers - General · 34 employees
JSPR vs SCLX FAQ
Which is bigger, Jasper Therapeutics or Scilex?
Scilex (SCLX) is larger, with a market capitalization of $20.82M compared with $18.63M for Jasper Therapeutics (JSPR).
Which stock has performed better over the past year, JSPR or SCLX?
SCLX returned -72.96% over the past 12 months, compared with -76.67% for JSPR (price return, excluding dividends). Past performance does not predict future results.
Are Jasper Therapeutics and Scilex in the same industry?
Both are in the Healthcare sector, but in different industries: Biotechnology for Jasper Therapeutics and Drug Manufacturers - General for Scilex.